tiprankstipranks
Advertisement
Advertisement

NGEN Stock Latest News

NervGen Pharma price target raised to $12 from $10 at Maxim
The FlyNervGen Pharma price target raised to $12 from $10 at Maxim
1d ago
NGEN
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
PremiumCompany Announcements
NervGen Wins FDA Alignment for Phase 3 RESTORE Trial in Chronic Tetraplegia
3d ago
NGEN
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
PremiumThe Fly
NervGen Pharma aligns with FDA on RESTORE study following End-of-Phase 2 meeting
3d ago
NGEN
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
PremiumThe Fly
NervGen Pharma price target lowered to $5.50 from $6.75 at Stifel
4d ago
NGEN
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
PremiumRatings
NervGen Pharma: Buy Rating on De‑Risked Path to Pivotal NVG-291 Trials and Compelling Risk‑Reward in Chronic Spinal Cord Injury
8d ago
NGEN
NervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
PremiumCompany AnnouncementsNervGen Maps Path to Phase 3 as NVG-291 Data Strengthen Neuroreparative Ambitions
9d ago
NGEN
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
Premium
Company Announcements
NervGen Pharma to Delist from TSX Venture Exchange, Keep Nasdaq Listing as NVG-291 Advances
28d ago
NGEN
NervGen Pharma to delist shares from TSX
Premium
The Fly
NervGen Pharma to delist shares from TSX
28d ago
NGEN
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
PremiumThe Fly
NervGen Pharma price target raised to C$6.75 from C$5 at Stifel
1M ago
NGEN
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
PremiumThe Fly
Nanogen appoints Ruff as Chief Regulatory Affairs Officer, McSherry as SVP
1M ago
NGEN
STOK
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
PremiumCompany Announcements
NervGen Pharma CFO to Retire as Company Advances Late-Stage SCI Program
2M ago
NGEN
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
PremiumCompany Announcements
NervGen Pharma Confirms Adam Rogers as CEO With New Equity-Rich Employment Deal
2M ago
6K
NGEN
NervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
PremiumCompany AnnouncementsNervGen Pharma Confirms Adam Rogers as CEO to Steer Next Growth Phase
2M ago
NGEN
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase
Premium
Company Announcements
NervGen Pharma Names Adam Rogers Permanent CEO to Drive Next Growth Phase
2M ago
NGEN
Nanogen names Adam Rogers as president and CEO, effective immediately
Premium
The Fly
Nanogen names Adam Rogers as president and CEO, effective immediately
2M ago
NGEN
Ten new option listings and two option delistings on January 22nd
PremiumThe FlyTen new option listings and two option delistings on January 22nd
3M ago
AVR
INR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >